An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of IXAZOMIB (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Trial Profile

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of IXAZOMIB (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ixazomib (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 25 Jun 2017 Results (n=61) assessing safety and efficacy, presented at the 22nd Congress of the European Haematology Association.
    • 12 Mar 2017 The trial has been completed in Czech Republic (end date: 2016-12-30).
    • 18 Feb 2017 The trial has been completed in Spain on 30-12-2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top